arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

NOVAVAX INC

NVAX
$9.77 ▼ -0.88 (-8.26%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
18 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
66
Health
Good
Bullish
auto_awesome

Analytical Summary

NOVAVAX INC shows strong fundamentals with top-quartile Profit Margin (%) and Operating Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $1.6B
Dividend Yield —
Revenue Growth 64.7% ↗
Op. Margin 40.3% ↗
ROIC -352.9% ↘
FCF / Share $-1.51 ↘
Trailing P/E 3.6x
Price / Book —
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

18-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$1.12B
↑ +64.7% —
Net Income Profit after all expenses
$440.30M
↑ +334.8% —
Operating Margin Operating profit as % of sales
40.3%
↑ +210.4% 94th
FCF / Share Free cash flow per share
$-1.51
↓ -163.4% —
trending_up

Bullish Indicators

  • Operating Margin (%)Operating Margin (%) is in the top quartile
  • Profit Margin (%)Profit Margin (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability
66
Financial Health
92
Cash Quality ↓
13

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 18 years · 68 quarters